Breaking News

Breaking News: Feds Appeal Rulings in Novartis and United Therapeutics 340B Contract Pharmacy Cases

The federal government yesterday asked the federal appeals court in Washington, D.C., to review a lower court's Nov. 5 joint ruling in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.

The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health care providers

Read More »

John Thune, Senate’s No. 2 Republican and Strong 340B Provider Ally, Weighs Retirement

U.S. Senate Minority Whip John Thune (R-S.D.), a strong 340B covered entity ally, is considering not running for re-election in 2022. | Gage Skidmore/Flickr

South Dakota U.S. Sen. John Thune, the second-ranking Senate Republican and a long-time 340B covered entity ally, might not run for re-election in 2022, two news organizations report.  It would be a significant blow to 340B providers who have counted

Read More »

Manchin’s Idea that VA Negotiate Medicare Drug Prices Could Adversely Impact 340B Program, Expert Suggests

Congress should let the VA negotiate drug prices on behalf of Medicare, U.S. Sen. Joe Manchin (W.Va.) reportedly told the Senate Democratic Caucus this week.

U.S. Sen. Joe Manchin (D-W.Va.) has suggested that the U.S. Department of Veterans Affairs (VA) be empowered to negotiate drug prices on behalf of Medicare, an initiative that may impact the 340B program if it should come to fruition.

Manchin

Read More »

N.Y. and Va. Health Centers Say Discovery Should Continue in their Novel 340B-Related Federal Lawsuit

The federal district court for western New York is hearing two 340B health centers' antitrust lawsuit against insulin and diabetes drug makers.

New York State and Virginia health centers asked a federal district judge on Monday to deny four insulin and diabetes drug manufacturers’ motion to pause fact-finding in the health centers’ antitrust suit stemming from the companies’ 340B contract pharmacy policies.

Read More »

Novo Nordisk and Sanofi Have Jan. 26 Deadline to File Opening Briefs in 340B Contract Pharmacy Appeal

The U.S. Third Circuit Court of Appeals will hear Novo Nordisk and Sanofi's 340B contract pharmacy lawsuits in tandem, just as a lower court did.

A federal appeals court in Philadelphia has given drug manufacturers Novo Nordisk and Sanofi a Jan. 26 deadline to file briefs seeking reversal of parts of a district judge’s Nov. 5 joint decision in the two companies’ 340B contract pharmacy

Read More »

HRSA Adds Three Days to 1Q 340B Registration Period

The first 340B covered entity registration period of the year will be Jan. 1-18, 2022, for an effective start date of April 1, 2022.

The first 340B covered entity registration period of the year will be Jan. 1-18, 2022, for an effective start date of April 1, 2022.

Eligible hospitals, health centers, clinics, and their child sites and contract pharmacies registered during the period

Read More »

More Than 850 Hospitals Ask Feds to Appeal Judge’s 340B Contract Pharmacy Ruling

850+ hospitals in the 340B program sent the HHS secretary a letter yesterday asking the government to appeal a judge’s 340B contract pharmacy ruling.

Just over 850 hospitals in the 340B program asked the federal government yesterday to appeal a judge’s Nov. 5 ruling that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and others use contract pharmacies. They

Read More »

Democratic Defection on Build Back Better Act Sets Back Drive to Lower Drug Prices

U.S. Sen. Joe Manchin’s (D-W.Va.) rejection of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.

West Virginia U.S. Sen. Joe Manchin’s rejection Sunday of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.

Manchin said of the BBA bill on Dec. 19, “I cannot vote to

Read More »

News Alert: Carole Johnson Will Take Over as HRSA Administrator in January

White House COVID-19 testing czar Carole Johnson will become the next head of the U.S. Health Resources and Services Administration in January.

White House COVID-19 testing czar and long-time Democratic health policy expert Carole Johnson will become the next head of the U.S. Health Resources and Services Administration (HRSA) in January.

HRSA Acting Administrator Diana Espinosa announced Johnson’s selection this afternoon via

Read More »

U.S. Retail Drug Spending Hit $348.4 Billion in 2020 but Overall Prices Fell 0.1%

U.S. retail prescription drug spending hit $348.4 billion in 2020 but overall prices declined slightly, a new federal report shows.

U.S. retail prescription drug spending hit $348.4 billion in 2020, constituting 8% of total health care expenditures, a new federal report shows.

The U.S. Centers for Medicare & Medicaid Services (CMS) yesterday published its annual national health care spending report

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report